The high mobility group A1 molecular switch: turning on cancer – can we turn it off?

Bibliography

• Shah SN, Cope L, Poh W, et al. HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS One 2013;8(5):e63419
   PubMed Web of Science ®Google Scholar
• Belton A, Gabrovsky A, Bae YK, et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 2012;7(1):e30034
   PubMed Web of Science ®Google Scholar
• Lund T, Holtlund J, Fredriksen M, Laland SG. On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett 1983;152(2):163-7
   PubMed Web of Science ®Google Scholar
• Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13(11):2439-46
   PubMed Web of Science ®Google Scholar
• Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001;1519(1-2):13-29
   PubMed Web of Science ®Google Scholar
• Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007;7(12):899-910
   PubMed Web of Science ®Google Scholar
• Resar LM. The high mobility group A1 gene: transforming inflammatory signals into cancer? Cancer Res 2010;70(2):436-9
   PubMed Web of Science ®Google Scholar
• Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40(5):499-507
   PubMed Web of Science ®Google Scholar
• Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415(6870):436-42
   PubMed Web of Science ®Google Scholar
• Dolde CE, Mukherjee M, Cho C, Resar LM. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 2002;71(3):181-91
   PubMedGoogle Scholar
• Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006;209(2):206-12
   PubMedGoogle Scholar
• Hillion J, Wood LJ, Mukherjee M, et al. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res 2009;7(11):1803-12
   PubMed Web of Science ®Google Scholar
• Hillion J, Dhara S, Sumter TF, et al. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res 2008;68(24):10121-7
   PubMedGoogle Scholar
• Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 2006;66(24):11613-22
   PubMedGoogle Scholar
• Hristov AC, Cope L, Di Cello F, et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 2010;23(1):98-104
   PubMedGoogle Scholar
• Shah SN, Resar LM. High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol 2012;27(5):567-79
   PubMedGoogle Scholar
• Roy S, Di Cello F, Kowalski J, et al. HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leuk Lymphoma 2013;54(11):2565-7
   PubMed Web of Science ®Google Scholar
• Johnson KR, Lehn DA, Elton TS, et al. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J Biol Chem 1988;263(34):18338-42
   PubMedGoogle Scholar
• Friedmann M, Holth LT, Zoghbi HY, Reeves R. Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 1993;21(18):4259-67
   PubMedGoogle Scholar
• Hristov AC, Cope L, Reyes MD, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 2009;22(1):43-9
   PubMed Web of Science ®Google Scholar
• Di Cello F, Hillion J, Hristov A, et al. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 2008;6(5):743-50
   PubMedGoogle Scholar
• Ikeda K, Mason PJ, Bessler M. 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood 2011;117(22):5860-9
   PubMedGoogle Scholar
• Moliterno AR, Resar LM. AKNA: another AT-hook transcription factor “hooking-up” with inflammation. Cell Res 2011;21(11):1528-30
   PubMedGoogle Scholar
• Resar LM, Brodsky RA. “Let”-ing go with clonal expansion? Blood 2011;117(22):5788-90
   PubMedGoogle Scholar
• Solomon MJ, Strauss F, Varshavsky A. A mammalian high mobility group protein recognizes any stretch of six A.T base pairs in duplex DNA. Proc Natl Acad Sci USA 1986;83(5):1276-80
   PubMedGoogle Scholar
• Reeves R, Nissen MS. The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 1990;265(15):8573-82
   PubMedGoogle Scholar
• Geierstanger BH, Volkman BF, Kremer W, Wemmer DE. Short peptide fragments derived from HMG-I/Y proteins bind specifically to the minor groove of DNA. Biochemistry 1994;33(17):5347-55
   PubMedGoogle Scholar
• Maher JF, Nathans D. Multivalent DNA-binding properties of the HMG-1 proteins. Proc Natl Acad Sci USA 1996;93(13):6716-20
   PubMedGoogle Scholar
• Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 1992;71(5):777-89
   PubMedGoogle Scholar
• Du W, Maniatis T. The high mobility group protein HMG I(Y) can stimulate or inhibit DNA binding of distinct transcription factor ATF-2 isoforms. Proc Natl Acad Sci USA 1994;91(24):11318-22
   PubMedGoogle Scholar
• Falvo JV, Thanos D, Maniatis T. Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 1995;83(7):1101-11
   PubMedGoogle Scholar
• Thanos D, Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 1995;83(7):1091-100
   PubMed Web of Science ®Google Scholar
• Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell 2007;129(6):1111-23
   PubMed Web of Science ®Google Scholar
• Apostolou E, Thanos D. Virus infection induces NF-kappaB-dependent interchromosomal associations mediating monoallelic IFN-beta gene expression. Cell 2008;134(1):85-96
   PubMedGoogle Scholar
• Ford E, Thanos D. The transcriptional code of human IFN-beta gene expression. Biochim Biophys Acta 2010;1799(3-4):328-36
   PubMedGoogle Scholar
• Saitoh Y, Laemmli UK. Metaphase chromosome structure: bands arise from a differential folding path of the highly AT-rich scaffold. Cell 1994;76(4):609-22
   PubMedGoogle Scholar
• Girard F, Bello B, Laemmli UK, Gehring WJ. In vivo analysis of scaffold-associated regions in drosophila: a synthetic high-affinity SAR binding protein suppresses position effect variegation. EMBO J 1998;17(7):2079-85
   PubMedGoogle Scholar
• Zhao K, Kas E, Gonzalez E, Laemmli UK. SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin. EMBO J 1993;12(8):3237-47
   PubMedGoogle Scholar
• Strick R, Laemmli UK. SARs are cis DNA elements of chromosome dynamics: synthesis of a SAR repressor protein. Cell 1995;83(7):1137-48
   PubMedGoogle Scholar
• Mirkovitch J, Mirault ME, Laemmli UK. Organization of the higher-order chromatin loop: specific DNA attachment sites on nuclear scaffold. Cell 1984;39(1):223-32
   PubMedGoogle Scholar
• Krech AB, Wulff D, Grasser KD, Feix G. Plant chromosomal HMGI/Y proteins and histone H1 exhibit a protein domain of common origin. Gene 1999;230(1):1-5
   PubMedGoogle Scholar
• Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58(18):4193-8
   PubMedGoogle Scholar
• Chiappetta G, Bandiera A, Berlingieri MT, et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995;10(7):1307-14
   PubMed Web of Science ®Google Scholar
• Dal Cin P, Fusco A, Belge G, et al. Involvement of the HMGI(Y) gene in a microfollicular adenoma of the thyroid. Genes Chromosomes Cancer 1999;24(3):286-9
   PubMedGoogle Scholar
• Kettunen E, Anttila S, Seppanen JK, et al. Differentially expressed genes in non small cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004;149(2):98-106
   PubMedGoogle Scholar
• Holth LT, Thorlacius AE, Reeves R. Effects of epidermal growth factor and estrogen on the regulation of the HMG-I/Y gene in human mammary epithelial cell lines. DNA Cell Biol 1997;16(11):1299-309
   PubMedGoogle Scholar
• Liu WM, Guerra-Vladusic FK, Kurakata S, et al. HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Cancer Res 1999;59(22):5695-703
   PubMedGoogle Scholar
• Flohr AM, Rogalla P, Bonk U, et al. High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 2003;18(4):999-1004
   PubMedGoogle Scholar
• Takaha N, Resar LM, Vindivich D, Coffey DS. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 2004;60(2):160-7
   PubMedGoogle Scholar
• Takaha N, Hawkins AL, Griffin CA, et al. High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res 2002;62(3):647-51
   PubMedGoogle Scholar
• Takeuchi I, Takaha N, Nakamura T, et al. High mobility group protein AT-hook 1 (HMGA1) is associated with the development of androgen independence in prostate cancer cells. Prostate 2012;72(10):1124-32
   PubMedGoogle Scholar
• Fedele M, Bandiera A, Chiappetta G, et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 1996;56(8):1896-901
   PubMedGoogle Scholar
• Chiappetta G, Manfioletti G, Pentimalli F, et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 2001;91(2):147-51
   PubMed Web of Science ®Google Scholar
• Cleynen I, Huysmans C, Sasazuki T, et al. Transcriptional control of the human high mobility group A1 gene: basal and oncogenic ras-regulated expression. Cancer Res 2007;67(10):4620-9
   PubMedGoogle Scholar
• Grade M, Hormann P, Becker S, et al. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 2007;67(1):41-56
   PubMedGoogle Scholar
• Abe N, Watanabe T, Masaki T, et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res 2000;60(12):3117-22
   PubMedGoogle Scholar
• Liau SS, Jazag A, Ito K, Whang EE. Overexpression of HMGA1 promotes anoikis resistance and constitutive akt activation in pancreatic adenocarcinoma cells. Br J Cancer 2007;96(6):993-1000
   PubMed Web of Science ®Google Scholar
• Liau SS, Rocha F, Matros E, et al. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 2008;113(2):302-14
   PubMedGoogle Scholar
• Liau SS, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008;14(5):1470-7
   PubMedGoogle Scholar
• Tesfaye A, Di Cello F, Hillion J, et al. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 2007;67(9):3998-4004
   PubMedGoogle Scholar
• Bandiera A, Bonifacio D, Manfioletti G, et al. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 1998;58(3):426-31
   PubMedGoogle Scholar
• Takaha N, Sowa Y, Takeuchi I, et al. Expression and role of HMGA1 in renal cell carcinoma. J Urol 2012;187(6):2215-22
   PubMed Web of Science ®Google Scholar
• Rho YS, Lim YC, Park IS, et al. High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol 2007;127(1):76-81
   PubMed Web of Science ®Google Scholar
• Giannini G, Cerignoli F, Mellone M, et al. High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res 2005;65(18):8308-16
   PubMedGoogle Scholar
• Giannini G, Cerignoli F, Mellone M, et al. Molecular mechanism of HMGA1 deregulation in human neuroblastoma. Cancer Lett 2005;228(1-2):97-104
   PubMedGoogle Scholar
• Cerignoli F, Ambrosi C, Mellone M, et al. HMGA molecules in neuroblastic tumors. Ann NY Acad Sci 2004;1028:122-32
   PubMedGoogle Scholar
• Giannini G, Kim CJ, Di Marcotullio L, et al. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. Br J Cancer 2000;83(11):1503-9
   PubMedGoogle Scholar
• Giannini G, Di Marcotullio L, Ristori E, et al. HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness. Cancer Res 1999;59(10):2484-92
   PubMedGoogle Scholar
• Rahman MM, Qian ZR, Wang EL, et al. Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer 2009;100(3):501-10
   PubMedGoogle Scholar
• Akaboshi S, Watanabe S, Hino Y, et al. HMGA1 is induced by wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer. Am J Pathol 2009;175(4):1675-85
   PubMedGoogle Scholar
• Chuma M, Saeki N, Yamamoto Y, et al. Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. Keio J Med 2004;53(2):90-7
   PubMedGoogle Scholar
• Wood LJ, Mukherjee M, Dolde CE, et al. HMG-I/Y, a new c-myc target gene and potential oncogene. Mol Cell Biol 2000;20(15):5490-502
   PubMedGoogle Scholar
• Pierantoni GM, Agosti V, Fedele M, et al. High-mobility group A1 proteins are overexpressed in human leukaemias. Biochem J 2003;372(Pt 1):145-50
   PubMedGoogle Scholar
• Xu Y, Sumter TF, Bhattacharya R, et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004;64(10):3371-5
   PubMedGoogle Scholar
• Karp JE, Smith BD, Resar LS, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011;117(12):3302-10
   PubMed Web of Science ®Google Scholar
• Nelson DM, Joseph B, Hillion J, et al. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 2011;52(10):1999-2006
   PubMed Web of Science ®Google Scholar
• Di Cello F, Dhara S, Hristov AC, et al. Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis. Leuk Lymphoma 2013;54(8):1762-8
   PubMed Web of Science ®Google Scholar
• Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60(15):4256-61
   PubMedGoogle Scholar
• Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001;21(2):575-94
   PubMedGoogle Scholar
• Shah SN, Kerr C, Cope L, et al. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One 2012;7(11):e48533
   PubMed Web of Science ®Google Scholar
• Hommura F, Katabami M, Leaner VD, et al. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res 2004;2(5):305-14
   PubMedGoogle Scholar
• Dhar A, Hu J, Reeves R, et al. Dominant-negative c-jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 2004;23(25):4466-76
   PubMedGoogle Scholar
• Chou B-K, Mali P, Huang X, et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with a unique epigenetic and gene expression signatures. Cell Res 2011;11:518-29
   Web of Science ®Google Scholar
• Bush BM, Brock AT, Deng JA, et al. The Wnt/beta-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer. Cell Biochem Funct 2013;31(3):228-36
   PubMedGoogle Scholar
• Munoz J, Stange DE, Schepers AG, et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent ‘+4’ cell markers. EMBO J 2012;31(14):3079-91
   PubMed Web of Science ®Google Scholar
• Zhou G, Chen J, Lee S, et al. The pattern of gene expression in human CD34(+) stem/progenitor cells. Proc Natl Acad Sci USA 2001;98(24):13966-71
   PubMedGoogle Scholar
• Fedele M, Fidanza V, Battista S, et al. Haploinsufficiency of the HMGA1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res 2006;66:2536-43
   PubMed Web of Science ®Google Scholar
• Fedele M, Pentimalli F, Baldassarre G, et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005;24(21):3427-35
   PubMedGoogle Scholar
• Schuldenfrei A, Belton A, Kowalski J, et al. HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics 2011;12:549
   PubMed Web of Science ®Google Scholar
• Yanagisawa BL, Resar L. Hitting the bull's eye: targeting HMGA1 in cancer stem cells. Expert Rev Anticancer Ther 2014;14(1):23-30
   PubMed Web of Science ®Google Scholar
• Wadkins RM, Tung CS, Vallone PM, Benight AS. The role of the loop in binding of an actinomycin D analog to hairpins formed by single-stranded DNA. Arch Biochem Biophys 2000;384(1):199-203
   PubMedGoogle Scholar
• Rajski SR, Williams RM. Observations on the covalent cross-linking of the binding domain (BD) of the high mobility group I/Y (HMG I/Y) proteins to DNA by FR66979. Bioorg Med Chem 2000;8(6):1331-42
   PubMedGoogle Scholar
• Beckerbauer L, Tepe JJ, Cullison J, et al. FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem Biol 2000;7(10):805-12
   PubMedGoogle Scholar
• Beckerbauer L, Tepe JJ, Eastman RA, et al. Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome. Chem Biol 2002;9(4):427-41
   PubMedGoogle Scholar
• Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997;37(2-3):117-32
   PubMedGoogle Scholar
• Pazdur R, Ho DH, Daugherty K, et al. Phase I trial of FK973: description of a delayed vascular leak syndrome. Invest New Drugs 1991;9(4):377-82
   PubMedGoogle Scholar
• Nakamura T, Masuda K, Matsumoto S, et al. Effect of FK973, a new antitumor antibiotic, on the cell cycle of L1210 cells in vitro. Jpn J Pharmacol 1989;49(3):317-24
   PubMedGoogle Scholar
• Naoe Y, Inami M, Matsumoto S, et al. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice. Jpn J Cancer Res 1998;89(12):1306-17
   PubMedGoogle Scholar
• Baron RM, Lopez-Guzman S, Riascos DF, et al. Distamycin A inhibits HMGA1-binding to the P-selectin promoter and attenuates lung and liver inflammation during murine endotoxemia. PLoS One 2010;5(5):e10656
   Google Scholar
• Grant MA, Baron RM, Macias AA, et al. Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter. Biochem J 2009;418(1):103-12
   PubMedGoogle Scholar
• Akhter MZ, Sharma A, Rajeswari MR. Interaction of adriamycin with a promoter region of HMGA1 and its inhibitory effect on HMGA1 expression in A431 human squamous carcinoma cell line. Mol Biosyst 2011;7(4):1336-46
   PubMedGoogle Scholar
• Pedulla ML, Treff NR, Resar LMS, Reeves R. Sequence and analysis of the murine Hmgiy (Hmga1) gene. Gene 2001;271(1):51-8
   PubMedGoogle Scholar
• Hillion J, Belton AM, Shah SN, et al. Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. Leuk Lymphoma 2013. [Epub ahead of print]
   Google Scholar
• Esposito F, Pierantoni GM, Battista S, et al. Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation. J Biol Chem 2009;284(38):25993-6004
   PubMedGoogle Scholar
• Maasch C, Vater A, Buchner K, et al. Polyetheylenimine-polyplexes of spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo. J Biol Chem 2010;285(51):40012-18
   PubMedGoogle Scholar
• Watanabe M, Sheriff S, Lewis KB, et al. HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines. Cancer Lett 2012;315(1):18-27
   PubMedGoogle Scholar
• Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110(5):979-86
   PubMed Web of Science ®Google Scholar
• Hillion J, Smail SS, Di Cello F, et al. The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology 2012;12(4):372-9
   PubMedGoogle Scholar
• Di Cello F, Hillion J, Kowalski J, et al. Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther 2008;7(7):2090-5
   PubMed Web of Science ®Google Scholar
• Baldassarre G, Belletti B, Battista S, et al. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene 2005;24(45):6809-19
   PubMedGoogle Scholar
• Sharma A, Ray R, Rajeswari MR. High-mobility group A1 (HMGA1) protein expression correlates with cisplatin-induced cell death in squamous cell carcinoma of skin. Cancer Invest 2010;28(4):340-9
   PubMedGoogle Scholar
• Scala S, Portella G, Fedele M, et al. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA 2000;97(8):4256-61
   PubMedGoogle Scholar
• Boylan NJ, Suk JS, Lai SK, et al. Highly compacted DNA nanoparticles with low MW PEG coatings: in vitro, ex vivo and in vivo evaluation. J Control Release 2012;157(1):72-9
   PubMedGoogle Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63:185-98
   PubMed Web of Science ®Google Scholar
• Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011;10(8):1470-80
   PubMed Web of Science ®Google Scholar
• Mussnich P, D'Angelo D, Leone V, et al. The high mobility group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. Mol Oncol 2013;7(3):531-42
   PubMedGoogle Scholar